Replimune's drug for advanced skin cancer fails to win FDA nod again - Reuters
Replimune's drug for advanced skin cancer fails to win FDA nod again Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"the company has no choice but to eliminate jobs and substantially scale back its U.S.-based manufacturing operations as a result of the decision."
— Sushil Patel , Executive
"decision on Tudriqev makes 'one less competitor' in the near-term for Iovance’s Amtagvi."
— Andrew Tsai , Executive
"the decision on Tudriqev makes 'one less competitor' in the near-term for Iovance’s Amtagvi."
— Andrew Tsai , Executive
Key People
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQV0xhbE5EbkRDa2l2OEdTdkhHRzlZU1cwdUM4bWt6ZGVTTWNIeFFUdHhDaW9SOHBiM3A3eV9VVTZoNXlRM0pNSk5adXJ1Vkw1SDZqSWI5aGlfT3B1VThsV21acFBVUU1RTE9oZXNSbHRMUlZTSzhNTGdXQTJELUgycm1QM0d5cGdQdlNicURjZEZ5LXVxa2t6MWh0aEI2N1o0UVM1X2VxMDAtb0t1T0pzSFdNTQ?oc=5" target="_blank">Replimune's drug for advanced skin cancer fails to win FDA nod again</a> <font color="#6f6f6f">Reuters</font>
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
The FDA declined to approve Replimune's RP1 drug for advanced skin cancer, citing insufficient data from studies, marking the second consecutive setback for the company.
Similar Stories
Related coverage based on topic and tags
Lawsuit against Bristol Myers over delayed cancer drug is revived - Reuters
Lawsuit against Bristol Myers over delayed cancer drug is revived Reuters
August 13, 2026 at 06:00 PMModerna shares surge as melanoma vaccine with Merck succeeds in large trial - reuters.com
Moderna shares surge as melanoma vaccine with Merck succeeds in large trial reuters.com
August 19, 2026 at 12:17 PMUS FDA approves Bristol Myers' blood cancer treatment - Reuters
US FDA approves Bristol Myers' blood cancer treatment Reuters
August 13, 2026 at 09:33 PMEyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
August 17, 2026 at 03:45 PMModerna, Merck breakthrough could usher in wave of cancer vaccines - Reuters
Moderna, Merck breakthrough could usher in wave of cancer vaccines Reuters
August 19, 2026 at 09:01 PMModerna shares double as cancer vaccine data rekindles investor hopes - Reuters
Moderna shares double as cancer vaccine data rekindles investor hopes Reuters
August 19, 2026 at 04:49 PM